Pembrolizumab With Anlotinib in Advanced Oral Mucosal Melanoma: A Retrospective Trial
Oral Diseases · 2026
DOI: 10.1111/odi.70206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2026. Verfasst von Yun Bi und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Stomatology, Shandong Second Medical University, Weifang, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Indoles, Quinolines, Melanoma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Clinical Research Project of Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Introduction
Oral mucosal melanoma (OMM) is a rare subtype of melanoma but exhibits highly invasive biological behavior. Programmed cell death protein 1 (PD‐1) monotherapy showed lower response in OMM than other subtypes of melanoma. Materials and Methods We retrospectively analyzed the efficacy and safety of pembrolizumab with anlotinib in patients with advanced OMM between August 2018 and September 2024. The primary endpoint was objective response rate (ORR); the secondary endpoints included disease control rate (DCR), duration of response (DOR), progression‐free survival (PFS), overall survival (OS), and treatment‐related adverse events (TRAEs).
Results
Forty‐one patients were enrolled in our study. Seventeen patients (41.4%) achieved an objective response. The median PFS was 6.4 months (95% confidence interval [CI], 4.5–8.3 months), and the median OS was 10.0 months (95% CI, 8.3–11.7 months). Thirty‐three patients (80.5%) experienced at least one TRAE. The most common TRAEs were hypertension (29.3%), hand‐foot syndrome (19.5%), and anemia (19.5%). Grade 3 or higher TRAEs occurred in two patients (4.8%), and no grade 5 TRAEs were observed.
Conclusions
Our study suggested that pembrolizumab with anlotinib in patients with advanced OMM showed potential efficacy and manageable adverse effects. Further studies are needed to confirm the efficacy of this combination strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Stomatology, Shandong Second Medical University, Weifang, China.
- Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- National Clinical Research Center of Stomatology, Shanghai, China.
ORCID-Profile: Chaoji Shi, Guoxin Ren, Jingzhou Hu
Förderung
- Clinical Research Project of Shanghai Municipal Health Commission
Zitieren
APA
Bi, Y., Yang, X., Lu, Y., Wu, Y., Shi, C., Ma, X., Song, H., Ju, H., Ren, G., & Hu, J. (2026). Pembrolizumab With Anlotinib in Advanced Oral Mucosal Melanoma: A Retrospective Trial. Oral Diseases. https://doi.org/10.1111/odi.70206
Vancouver
Bi Y, Yang X, Lu Y, Wu Y, Shi C, Ma X, et al. Pembrolizumab With Anlotinib in Advanced Oral Mucosal Melanoma: A Retrospective Trial. Oral Diseases. 2026. doi:10.1111/odi.70206
BibTeX
@article{Bi2026,
author = {Bi, Yun and Yang, Xinwei and Lu, Yusheng and Wu, Yunteng and Shi, Chaoji and Ma, Xuhui and Song, Hao and Ju, Houyu and Ren, Guoxin and Hu, Jingzhou},
title = {Pembrolizumab With Anlotinib in Advanced Oral Mucosal Melanoma: A Retrospective Trial},
journal = {Oral Diseases},
year = {2026},
doi = {10.1111/odi.70206}
}
EUVIMED